Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin‐Biroulet, Toshimitsu Fujii, Jessica R. Allegretti et al.|Gastroenterology|2023Cited by 97
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesDavid T. Rubin, Patrick Chamouard, Jessica R. Allegretti et al.|The Lancet|2024Cited by 95
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel diseaseBrian G. Feagan, Chenglong Han, William J. Sandborn et al.|Journal of Patient-Reported Outcomes|2023Cited by 16
759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDYDavid T. Rubin, Axel Dignaß, Jessica R. Allegretti et al.|Gastroenterology|2024Cited by 14
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel DiseaseBruce E. Sands, Chenglong Han, Natalie A. Terry et al.|Value in Health|2024Cited by 10